Luminopia Raises $5.7M in Seed Extension Financing

▤ Summary

The round was led by ShangBay Capital, with participation from Sony Innovation Fund, The Vertical Group, and SSI Strateg. With the closing of the round, William Dai, Founding Managing Partner of ShangBay Capital, will be joining Luminopia’s Board of Directors. The company intends to us the funds for a staged rollout of its lead product for amblyopia to pediatric ophthalmologists starting this month, before expanding to a broader launch in the second half of 2023. The company is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. Upon launch, the therapeutic will be prescribed by eye care professionals and distributed through an online retail pharmacy.

▦ Linked Companies